Analysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $85.25

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have earned a consensus rating of “Moderate Buy” from the four research firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $85.25.

Several analysts recently issued reports on PBH shares. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research report on Monday, December 9th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Tuesday. Jefferies Financial Group restated a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PBH. Victory Capital Management Inc. boosted its stake in shares of Prestige Consumer Healthcare by 9.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after purchasing an additional 171,357 shares in the last quarter. Arizona State Retirement System lifted its stake in Prestige Consumer Healthcare by 1.9% in the second quarter. Arizona State Retirement System now owns 13,900 shares of the company’s stock worth $957,000 after purchasing an additional 264 shares during the last quarter. Norden Group LLC boosted its position in Prestige Consumer Healthcare by 25.9% during the second quarter. Norden Group LLC now owns 12,435 shares of the company’s stock valued at $856,000 after buying an additional 2,559 shares during the period. Quest Partners LLC grew its stake in shares of Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares during the last quarter. Finally, Choreo LLC purchased a new position in shares of Prestige Consumer Healthcare in the second quarter worth about $677,000. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $73.91 on Friday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare has a twelve month low of $58.18 and a twelve month high of $86.36. The company has a fifty day moving average of $80.53 and a 200-day moving average of $74.14. The firm has a market capitalization of $3.65 billion, a P/E ratio of 17.98, a P/E/G ratio of 2.32 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.07 earnings per share. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.